SCN1A and epilepsy: This is the first study to utilize a cell-specific ablation strategy for TAU in-vivo, and interestingly the first TAU-ASO strategy to treat a genetic model of epilepsy with a completely unrelated etiology (Nav1.1 haploinsufficiency affecting inhibitory neurons).